ABT · 10-Q · 2026Q2 · Full report
Interest Expense Increase
ABBOTT LABORATORIES · 2026-07-28 · Importance 71 · Surprise 82 · No source text
Net interest expense increased by $268 million, or approximately 271%, to $367 million in the first six months of 2026. The increase primarily reflected interest on debt incurred to finance the Exact Sciences acquisition. Abbott also reported a $249 million increase in second-quarter interest expense to $299 million and expects to maintain an investment-grade rating, with long-term ratings of A+ from S&P Global Ratings and Aa3 from Moody’s.
Key facts
- Abbott issued $20.0 billion of debt in March 2026 comprising multiple tranches: $1,000 million SOFR+50 bp Senior notes due 2029; $2,250 million 3.700% Senior notes due 2029; $2,500 million 4.000% Senior notes due 2031; $2,750 million 4.300% Senior notes due 2033; $3,750 million 4.650% Senior notes due 2036; $2,000 million 4.750% Senior notes due 2038; $3,750 million 5.500% Senior notes due 2056; $2,000 million 5.600% Senior notes due 2066.
- Interest expense, net increased by $249 million to $299 million in the second quarter of 2026 and increased by $268 million to $367 million in the first six months of 2026.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | realized | — | Abbott issued $20.0 billion of debt in March 2026 comprising multiple tranches: $1,000 million SOFR+50 bp Senior notes due 2029; $2,250… |